Global Information
회사소개 | 문의 | 위시리스트

주목 시장 분석 : 아토피성 피부염

Market Spotlight: Atopic Dermatitis

리서치사 Datamonitor Healthcare
발행일 2020년 01월 상품 코드 858316
페이지 정보 영문 68 Pages
가격
US $ 1,318 ₩ 1,604,000 PDF by E-mail (Single User License)


주목 시장 분석 : 아토피성 피부염 Market Spotlight: Atopic Dermatitis
발행일 : 2020년 01월 페이지 정보 : 영문 68 Pages

세계의 아토피성 피부염(Atopic Dermatitis) 치료 시장을 조사했으며, 질환의 배경과 개요, 주요 치료법, 주요 파이프라인 의약품 개요, 주요 출시 의약품 동향, 라이선싱 및 자산 인수 등 기업간 주요 거래 동향, 특허 정보, 임상시험 상황 등의 정보를 정리했습니다.

개요

요점

질환의 배경

  • 질환 정의
  • 환자 세분화
  • 증상
  • 위험인자
  • 진단

치료

  • 비약리학적 개입
  • 투약 치료
  • 전신 치료
  • 생물학적 요법
  • 광선 요법
  • 보조 요법

역학

출시 의약품

파이프라인 의약품

최근 동향과 애널리스트의 견해

가까운 미래의 동향

주요 규제 동향

성공 확률

라이선싱/자산 인수 등의 거래

원특허권(Parent Patent)

매출 기회

임상시험 환경

  • 스폰서 : 진행 상황별
  • 스폰서 : 단계별
  • 최근 동향

문헌

  • 처방 정보

부록

LSH 20.02.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Overview:

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. The condition usually begins during early infancy and childhood, but can persist into, or start during, adulthood. AD usually fluctuates between periods of relative flares and quiescence; however, some individuals have chronically active disease. The exact cause of the disease is unknown; however, certain factors such as epigenetic, genetic, immunological, and environmental interactions with overlapping skin barrier defects are indicated in its pathogenesis. The disease significantly affects the quality of life of the patient and their family, which further causes serious socioeconomic consequences. An imbalance of the Th22 and Th2 cytokines which causes the disruption of keratinocytes is thought to be an important contributing factor that drives AD pathogenesis. Furthermore, impaired skin barrier function due to mutations in the epidermal barrier protein, filaggrin, could also play a crucial role in the development of AD by increasing the penetration of microbes and allergens.

Key Takeaways:

The approved drugs in the atopic dermatitis space focus on a wide variety of targets. These drugs are commonly administered via the topical route, with a few select products being available in oral, intramuscular, intravenous, and subcutaneous formulations.

The majority of industry-sponsored drugs in active clinical development for atopic dermatitis are in Phase II. Pipeline drugs in development for atopic dermatitis focus on a wide variety of targets. The largest proportion of drugs in development are administered via the topical route, with the remainder being oral, subcutaneous, intravenous, transdermal, and intranasal formulations.

High-impact upcoming events for drugs in the atopic dermatitis space comprise topline Phase II, Phase IIb, Phase II/III, and Phase III trial results, as well as an expected European approval decision.

The overall likelihood of approval of a Phase I allergy asset is 13.8%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.6 years from Phase I to approval in the overall allergy space.

There have been 28 licensing and asset acquisition deals involving atopic dermatitis drugs during 2015-20. The largest deal was the $1,445m option and license agreement between Almirall and Dermira in 2019 to develop and commercialize lebrikizumab for the treatment or prevention of atopic dermatitis and certain other indications in Europe.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for atopic dermatitis have been in the early and mid-phases of development, with 66% of trials in Phase I-II, and 34% in Phase III-IV.

The US has a substantial lead in the number of atopic dermatitis clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the atopic dermatitis space is dominated by completed trials. Novartis has the highest number of completed clinical trials for atopic dermatitis, with 71 trials.

Novartis leads the industry sponsors with the highest number of clinical trials for atopic dermatitis, followed by Pfizer.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Non-pharmacologic interventions
  • Medications
  • Systemic treatment
  • Biologic therapy
  • Phototherapy treatment
  • Adjunctive treatment

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Tralokinumab for Atopic Dermatitis (December 11, 2019)
  • Etokimab for Atopic Dermatitis (November 8, 2019)
  • Abrocitinib for Atopic Dermatitis (September 27, 2019)
  • Olumiant for Atopic Dermatitis (August 23, 2019)
  • ATI-502 for Atopic Dermatitis (August 8, 2019)
  • Mapracorat for Atopic Dermatitis (June 25, 2019)
  • Abrocitinib for Atopic Dermatitis (May 15, 2019)
  • Nemolizumab for Atopic Dermatitis (April 18, 2019)
  • Lebrikizumab for Atopic Dermatitis (March 18, 2019)
  • LEO 124249 for Atopic Dermatitis (March 1, 2019)
  • Lebrikizumab for Atopic Dermatitis (February 12, 2019)
  • Olumiant for Atopic Dermatitis (February 4, 2019)
  • DS107 for Atopic Dermatitis (October 3, 2018)
  • PR022 for Atopic Dermatitis (August 14, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Getting A Good Start: Sanofi Extends Dupixent's Potential To Younger Patients
  • CHMP Delivers More Good News For Sanofi's Dupixent
  • Dupixent Gets Expanded Label With Pediatric Dermatitis Indication

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Janssen Licenses Global Rights To XBiotech's Bermekimab
  • Seneca Moves Towards Antibody In-Licensing Deal With China's QYuns
  • Leo Options Two Protein-Degradation Candidates Under Existing Alliance With Ubiquigent
  • Almirall Pays $50m To Stick With Dermira's Lebrikizumab
  • Almirall Keeps Up In Dermatitis With Platform Collaboration
  • Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal
  • Deals Shaping The Medical Industry, January 2019

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for atopic dermatitis in the US
  • Figure 2: Pipeline drugs for atopic dermatitis, by company
  • Figure 3: Pipeline drugs for atopic dermatitis, by drug type
  • Figure 4: Pipeline drugs for atopic dermatitis, by classification
  • Figure 5: Etokimab for Atopic Dermatitis (November 8, 2019): Phase IIb - ATLAS
  • Figure 6: Abrocitinib for Atopic Dermatitis (September 27, 2019): Phase III - JADE Mono-2
  • Figure 7: Olumiant for Atopic Dermatitis (August 23, 2019): Phase III - BREEZE-AD7 (TCS Add-On; Ex-US)
  • Figure 8: ATI-502 for Atopic Dermatitis (August 8, 2019): Phase II - AD-201
  • Figure 9: Abrocitinib for Atopic Dermatitis (May 15, 2019): Phase III - JADE Mono-1
  • Figure 10: Nemolizumab for Atopic Dermatitis (April 18, 2019): Phase III - Moderate to Severe Pruritus (Japan)
  • Figure 11: Lebrikizumab for Atopic Dermatitis (March 18, 2019): Phase IIb - Dose-Ranging Study
  • Figure 12: LEO 124249 for Atopic Dermatitis (March 1, 2019): Phase IIa - Proof of Concept (Germany)
  • Figure 13: Olumiant for Atopic Dermatitis (February 4, 2019): Phase III - BREEZE-AD1 (Mono), Phase III - BREEZE-AD2 (Mono)
  • Figure 14: DS107 for Atopic Dermatitis (October 3, 2018): Phase IIb - ADvantage
  • Figure 15: PR022 for Atopic Dermatitis (August 14, 2018): Phase IIa - Multiple Doses
  • Figure 16: Key upcoming events in atopic dermatitis
  • Figure 17: Probability of success in the atopic dermatitis pipeline
  • Figure 18: Licensing and asset acquisition deals in atopic dermatitis, 2015-20
  • Figure 19: Parent patents in atopic dermatitis
  • Figure 20: Clinical trials in atopic dermatitis
  • Figure 21: Top 10 drugs for clinical trials in atopic dermatitis
  • Figure 22: Top 10 companies for clinical trials in atopic dermatitis
  • Figure 23: Trial locations in atopic dermatitis
  • Figure 24: Atopic dermatitis trials sponsors by status
  • Figure 25: Atopic dermatitis trials sponsors by phase

LIST OF TABLES

  • Table 1: Marketed drugs for atopic dermatitis
  • Table 2: Pipeline drugs for atopic dermatitis in the US
  • Table 3: Tralokinumab for Atopic Dermatitis (December 11, 2019)
  • Table 4: Etokimab for Atopic Dermatitis (November 8, 2019)
  • Table 5: Abrocitinib for Atopic Dermatitis (September 27, 2019)
  • Table 6: Olumiant for Atopic Dermatitis (August 23, 2019)
  • Table 7: ATI-502 for Atopic Dermatitis (August 8, 2019)
  • Table 8: Mapracorat for Atopic Dermatitis (June 25, 2019)
  • Table 9: Abrocitinib for Atopic Dermatitis (May 15, 2019)
  • Table 10: Nemolizumab for Atopic Dermatitis (April 18, 2019)
  • Table 11: Lebrikizumab for Atopic Dermatitis (March 18, 2019)
  • Table 12: LEO 124249 for Atopic Dermatitis (March 1, 2019)
  • Table 13: Lebrikizumab for Atopic Dermatitis (February 12, 2019)
  • Table 14: Olumiant for Atopic Dermatitis (February 4, 2019)
  • Table 15: DS107 for Atopic Dermatitis (October 3, 2018)
  • Table 16: PR022 for Atopic Dermatitis (August 14, 2018)
  • Table 17: Historical global sales, by drug ($m), 2014-18
  • Table 18: Forecasted global sales, by drug ($m), 2020-24
Back to Top
전화 문의
F A Q